Toxicities Rare After Two Weeks of CAR T-Cell Therapy Infusion

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, July 30, 2024 -- New-onset cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are rare beyond two weeks following infusion of CD19-directed chimeric antigen receptor T (CAR T)-cell therapies, according to a study published online July 23 in Blood Advances.

Noting that the U.S. Food and Drug Administration has mandated that patients should remain close to treatment centers for four weeks to monitor and manage toxicity risks associated with CD19-directed CAR T-cell therapies, including CRS and ICANS, Nausheen Ahmed, M.D., from the University of Kansas Medical Center in Westwood, and colleagues conducted a retrospective cohort study involving 475 patients infused with axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel from 2018 to 2023 to assess onset and duration of CRS and ICANS.

The researchers found that although there were differences in the incidence and duration of CRS and ICANS between CAR T-cell products, new-onset CRS and ICANS were extremely rare after two weeks following infusion, occurring in 0 and 0.7 percent, respectively. After two weeks, there were no new cases of CRS, while a single case of new-onset ICANS occurred in the third week following infusion. In the early follow-up period, nonrelapse mortality was driven by ICANS (1.1 percent until day 28), followed by infection through three months postinfusion (1.2 percent).

"These data support further investigation into individualized monitoring strategies for stable patients," the authors write. "A flexible monitoring period may help to decrease financial and geographic limitations for patients and make CAR T more accessible and feasible."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-07-31 01:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords